viral
urti
usual
preced
abr
allergi
anoth
inflammatori
condit
nose
paranas
sinus
may
also
predispos
individu
develop
abr
virus
caus
infect
upper
airway
includ
rhinoviru
coronaviru
influenza
b
virus
parainfluenza
viru
respiratori
syncyti
viru
rsv
adenoviru
viral
infect
occur
earli
fall
earli
spring
manifest
common
cold
incid
sinus
higher
time
viral
urti
stimul
increas
inflamm
local
immun
respons
nasopharynx
surround
mucosa
virus
influenza
viru
produc
signific
mucos
damag
other
promot
local
product
cytokin
inflammatori
mediat
lead
sign
symptom
common
cold
ie
viral
urti
numer
cytokin
proinflammatori
mediat
eg
histamin
leukotrien
prostaglandin
upregul
abr
episod
virus
suppress
effect
function
neutrophil
macrophag
lymphocyt
includ
diminish
adher
chemotact
phagocyt
oxid
secretori
bactericid
function
neutrophil
virus
also
decreas
function
macrophag
lymphocyt
result
patient
viral
urti
gener
vulner
secondari
overgrowth
subsequ
bacteri
infect
pathogen
colon
nasopharynx
streptococcu
pneumonia
haemophilu
influenza
colon
nontyp
h
influenza
significantli
affect
concurr
infect
rsv
howev
site
bacteri
attach
known
mechan
attach
involv
upregul
express
epitheli
receptor
includ
intercellular
adhes
attach
site
pneumonia
may
also
expos
role
allergi
play
abr
blair
et
al
instil
pneumonia
ongo
nasal
allerg
inflamm
mous
model
found
allergi
augment
infect
result
inflammatori
respons
also
show
allergi
alon
allergen
exposur
enhanc
sinu
infect
suggest
local
inflamm
import
scientif
basi
role
allergi
play
abr
includ
follow
theori
releas
mediat
mast
cell
allerg
reaction
caus
greater
transud
fluid
increas
prolifer
bacteria
sinu
caviti
inflammatori
mediat
releas
eosinophil
allerg
reaction
expos
epitheli
pneumonia
bind
site
ciliari
transport
sinus
alter
allerg
inflamm
reduc
clearanc
bacteria
symptom
rhinosinus
consequ
activ
inflammatori
pathway
parasympathet
nervou
system
fever
myalgia
pharyng
frequent
associ
viral
urti
usual
resolv
approxim
day
nasal
congest
postnas
drainag
cough
may
persist
second
third
week
notabl
chang
color
nasal
discharg
suggest
presenc
bacteri
infect
determin
point
time
secondari
bacteri
infect
develop
becom
clinic
diagnost
dilemma
lacroix
et
al
studi
patient
urti
report
distinct
sign
symptom
patient
mildtomoder
clinic
present
predict
presenc
pathogen
bacteria
accord
abr
treatment
guidelin
sinu
allergi
health
partnership
sahp
clinic
diagnosi
abr
may
made
urti
symptom
eg
nasal
congest
facial
pressur
andorpain
especi
unilater
postnas
drip
worsen
day
improv
day
howev
identif
specif
sign
symptom
clinic
examin
appear
reliabl
predict
bacteri
infect
radiographi
provid
moder
sensit
moder
specif
diagnosi
abr
neg
result
plainfilm
radiographi
better
predict
valu
posit
result
plainfilm
radiograph
valuabl
visual
frontal
maxillari
sinus
use
infect
ethmoid
origin
plainfilm
radiograph
also
reveal
extent
diseas
furthermor
abnorm
find
plainfilm
radiograph
differenti
viral
bacteri
diseas
group
patient
suspect
bacteri
abr
posit
find
radiograph
sinu
tap
yield
pathogen
bacteria
ct
mri
recommend
patient
abr
may
valuabl
patient
complic
episod
sinu
punctur
aspir
cultur
refer
standard
identifi
bacteri
episod
although
basic
research
tool
expert
believ
posit
result
bacteriolog
cultur
nasopharyng
aspir
best
identifi
patient
may
benefit
antibiot
treatment
idea
also
propos
kaiser
et
al
patient
urti
nasopharyng
cultur
posit
h
influenza
moraxella
catarrhali
pneumonia
among
patient
proven
bacteri
infect
rate
clinic
cure
among
patient
given
amoxicillinclavulan
therapi
time
higher
symptom
score
day
significantli
lower
compar
patient
given
placebo
addit
studi
need
valid
theori
talbot
et
al
report
cultur
obtain
rigid
nasal
endoscopi
compar
obtain
sinu
punctur
aspir
endoscop
cultur
sensit
specif
posit
predict
valu
neg
predict
valu
accuraci
studi
largest
date
demonstr
endoscop
sampl
compar
favor
punctur
aspir
identifi
major
pathogen
caus
abr
summari
diagnosi
rhinosinus
typic
made
clinic
present
bacteri
episod
like
symptom
persist
week
imag
techniqu
indic
case
seen
routin
clinic
practic
microbiolog
sampl
techniqu
use
clinic
investig
albeit
caveat
sensit
major
pathogen
respons
abr
adult
pneumonia
h
influenza
although
report
percentag
vari
recent
tap
studi
identifi
pneumonia
h
influenza
isol
total
isol
use
conjug
pneumococc
vaccin
pediatr
popul
may
respons
increas
preval
h
influenza
adult
rhinosinus
surveil
studi
use
monitor
chang
resist
among
major
pathogen
alexand
project
surveil
network
examin
suscept
pathogen
involv
communityacquir
respiratori
tract
infect
adult
recent
report
isol
pneumonia
isol
h
influenza
isol
catarrhali
collect
countri
among
pneumonia
isol
worldwid
preval
resist
penicillin
mic
mgl
resist
macrolid
erythromycin
mic
mgl
unit
state
pneumonia
isol
demonstr
resist
penicillin
worldwid
preval
fluoroquinoloneresist
pneumonia
ofloxacin
mic
mgl
low
preval
h
influenza
catarrhali
isol
respect
surveil
studi
h
influenza
catarrhali
highli
suscept
test
fluoroquinolon
anoth
surveil
trust
global
chang
resist
pattern
among
common
sinu
pathogen
sahm
et
al
report
pneumonia
increas
resist
penicillin
detect
china
thailand
increas
resist
azithromycin
detect
china
germani
hong
kong
thailand
unit
kingdom
multidrug
resist
increas
china
countri
incid
remain
similar
incid
report
countri
combin
rate
resist
levofloxacin
remain
low
studi
year
h
influenza
increas
product
detect
franc
germani
south
africa
unit
kingdom
studi
pneumonia
sinu
isol
collect
consecut
respiratori
tract
infect
season
unit
state
test
panel
antimicrobi
use
nccl
broth
microdilut
among
pneumonia
sinu
isol
collect
isol
suscept
penicillin
suscept
azithromycin
erythromycin
suscept
cefuroxim
suscept
amoxicillinclavulan
suscept
levofloxacin
levofloxacin
gatifloxacin
moxifloxacin
demonstr
equival
suscept
levofloxacinresist
isol
identifi
multidrugresist
phenotyp
ie
resist
antimicrobi
class
account
isol
resist
penicillin
azithromycin
trimethoprimsulfamethoxazol
tmpsmz
common
multidrugresist
phenotyp
strain
phenotyp
suscept
levofloxacin
although
remain
difficult
determin
patient
receiv
antimicrobi
therapi
antibacteri
consid
benefici
treatment
known
suspect
bacteri
episod
sinus
landmark
agenc
health
care
polici
research
guidelin
identifi
studi
met
criteria
metaanalysi
evalu
benefit
antibacteri
versu
antibacteri
treatment
abr
shown
figur
significantli
effect
clinic
cure
onethird
case
reduc
treatment
failur
onehalf
compar
placebo
accord
french
expert
antibiot
treatment
modifi
treatment
acut
purul
maxillari
sinus
indic
drainag
wash
paranas
sinus
rare
histor
data
preantibiot
era
also
confirm
treatment
acut
diseas
antibacteri
reduc
thrombophlebit
cn
orbit
complic
purul
sinus
although
data
support
use
antibacteri
develop
resist
sever
key
respiratori
pathogen
led
new
paradigm
treat
abr
antibacteri
approv
us
food
drug
administr
may
longer
pharmacokineticpharmacodynam
profil
need
provid
optim
bacteri
kill
treatment
guidelin
manag
abr
develop
sever
expert
group
throughout
world
brief
review
find
recommend
present
us
guidelin
sahp
publish
guidelin
thoroughli
review
variou
aspect
abr
emphasi
appropri
antibiot
choic
era
resist
work
guidelin
began
center
diseas
control
prevent
drugresist
streptococcu
pneumonia
therapeut
work
group
publish
articl
treatment
acut
otiti
media
era
resist
pneumococci
sahp
recent
revis
guidelin
consid
chang
occur
antibiot
resist
pattern
current
sahp
treatment
guidelin
base
mathemat
model
abr
treatment
predict
bacteriolog
clinic
efficaci
antibacteri
accord
pathogen
distribut
rate
spontan
resolut
without
treatment
vitro
microbiolog
activ
pharmacokineticpharmacodynam
break
point
accord
model
best
data
use
antibacteri
place
follow
rel
rank
order
accord
predict
clinic
efficaci
adult
respiratori
fluoroquinolon
ie
moxifloxacin
gatifloxacin
levofloxacin
ceftriaxon
highdos
amoxicillinclavulan
g
amoxicillinday
mg
clavulanateday
highdos
amoxicillin
gday
amoxicillin
gday
cefpodoxim
proxetil
cefixim
basi
h
influenza
catarrhali
coverag
cefuroxim
axetil
cefdinir
tmpsmz
doxycyclin
clindamycin
basi
gramposit
coverag
azithromycin
clarithromycin
erythromycin
telithromycin
cefaclor
loracarbef
figur
predict
rate
spontan
resolut
among
patient
clinic
diagnosi
abr
sahp
guidelin
divid
patient
abr
gener
categori
mild
diseas
receiv
antibacteri
within
past
week
mild
diseas
receiv
antibacteri
within
past
week
moder
diseas
regardless
recent
antibiot
exposur
term
mild
moder
defin
leav
definit
sever
clinic
judgment
healthcar
provid
patient
receiv
recent
antibiot
therapi
moder
diseas
like
infect
resist
organ
patient
also
concern
longterm
consequ
treatment
fail
current
sahp
recommend
initi
therapi
adult
patient
mild
diseas
receiv
antibacteri
previou
week
includ
follow
option
amoxicillinclavulan
g
amoxicillinday
mg
clavulanateday
amoxicillin
gday
cefpodoxim
proxetil
cefuroxim
axetil
cefdinir
tmpsmz
doxycyclin
macrolidesazalidesketolid
ie
azithromycin
clarithromycin
erythromycin
telithromycin
may
consid
patient
allergi
tabl
improv
h
patient
treatment
switch
respiratori
fluoroquinolon
highdos
amoxicillinclavulan
ceftriaxon
gday
day
combin
therapi
eg
highdos
amoxicillin
clindamycin
plu
cefixim
rifampin
adult
mild
diseas
receiv
antibacteri
previou
week
adult
moder
diseas
may
treat
respiratori
fluoroquinolon
highdos
amoxicillinclavulan
howev
sahp
warn
widespread
use
respiratori
fluoroquinolon
patient
milder
diseas
may
promot
resist
wide
spectrum
organ
class
agent
ceftriaxon
combin
therapi
adequ
coverag
gramposit
neg
bacteria
may
also
consid
ie
highdos
amoxicillin
clindamycin
plu
cefixim
rifampin
french
guidelin
french
treatment
guidelin
recommend
follow
firstlin
agent
treatment
adult
patient
abr
amoxicillinclavulan
secondgener
oral
cephalosporin
cefuroxim
axetil
thirdgener
oral
cephalosporin
cefpodoxim
proxetil
pristinamycin
natur
occur
streptogramin
avail
unit
state
also
recommend
fluoroquinolon
activ
pneumonia
reserv
patient
firstlin
treatment
fail
french
agenc
sanitari
safeti
health
product
also
state
amoxicillin
macrolid
longer
recommend
firstlin
treatment
abr
per
guidelin
antimicrobi
treatment
cours
advis
guidelin
also
suggest
shortcours
adjunct
corticosteroid
therapi
may
benefici
patient
german
guidelin
german
sinu
treatment
guidelin
recommend
amoxicillin
empir
firstlin
therapi
mani
altern
list
guidelin
includ
inhibitor
combin
secondgener
oral
cepahlosporin
macrolid
ketolid
tmpsmz
doxcyclin
clindamycin
patient
moresever
diseas
risk
factor
firstlin
therapi
fail
amoxicillinclavulan
secondgener
cephalosporin
altern
respiratori
fluoroquinolon
thirdgener
cephalosporin
recommend
therapi
spanish
guidelin
treatment
guidelin
abr
also
publish
spanish
societi
chemotherapi
spanish
societi
otorhinolaryngolog
cervicofaci
patholog
recommend
base
follow
suscept
data
geograph
region
pneumonia
highli
suscept
moxifloxacin
levofloxacin
telithromycin
highdos
amoxicillin
howev
high
resist
rate
cefaclor
cefuroxim
cefpodoxim
macrolid
observ
spain
h
influenza
usual
suscept
moxifloxacin
levofloxacin
amoxicillinclavulan
cefuroxim
cefixim
approxim
h
influenza
strain
posit
immunocompet
patient
mild
maxillari
diseas
comorbid
either
treatment
amoxicillin
recommend
patient
moder
infect
includ
patient
underli
immunosuppress
comorbid
frontalsphenoid
diseas
respiratori
fluoroquinolon
firstlin
choic
thirdgener
cephalosporin
advis
patient
sever
complic
episod
respiratori
fluoroquinolon
excel
activ
h
influenza
catarrhali
well
potenc
pneumonia
although
remain
question
proper
role
fluoroquinolon
treatment
abr
fluoroquinolon
appear
highli
effect
secondlin
therapi
firstlin
therapi
certain
sicker
patient
sahp
recommend
fluoroquinolon
use
state
fluoroquinolon
use
indiscrimin
pharmacodynam
potent
fluoroquinolon
use
treat
suspect
pathogen
decis
made
use
fluoroquinolon
prefer
given
agent
like
achiev
optim
pharmacokineticpharmacodynam
paramet
page
pneumonia
pharmacodynam
increas
demand
promot
moresens
antimicrobi
use
potent
antimicrobi
therapi
must
care
select
target
suspect
pathogen
minim
emerg
resist
mutant
among
pathogen
commonli
associ
abr
pneumonia
key
pathogen
respiratori
fluoroquinolon
vari
potenc
pharmacodynam
properti
optim
clinic
bacteriolog
success
patient
pneumococc
sinus
episod
prevent
select
resist
mutant
examin
key
pharmacodynam
measur
cmax
mic
area
plasma
concentr
auc
mic
valu
includ
concentr
prevent
select
resist
mutant
need
consid
commonli
report
valu
pneumonia
steadyst
auc
valu
correct
protein
bind
use
auc
mic
valu
respiratori
fluoroquinolon
follow
moxifloxacin
mgday
gatifloxacin
mgday
levofloxacin
mgday
levofloxacin
mgday
basi
premis
auc
mic
must
exceed
pneumonia
achiev
desir
patient
success
moxifloxacin
gatifloxacin
highdos
levofloxacin
consist
exceed
suggest
minimum
ratio
import
pharmacodynam
limit
serum
concentr
evalu
target
tissu
site
two
studi
shown
moxifloxacin
achiev
high
concentr
sinu
tissu
follow
administr
singl
oral
dose
mg
patient
dini
et
al
found
moxifloxacin
distribut
extens
throughout
inflam
noninflam
sinu
mucsoa
although
concentr
highest
maxillari
sinu
tissuetoblood
ratio
site
second
studi
gehanno
et
al
measur
moxifloxacin
concentr
sinu
tissu
steadyst
condit
ie
mgday
day
reach
patient
chronic
sinus
concentr
moxifloxacin
sinu
mucosa
consist
higher
plasma
mgkg
h
administr
dose
versu
mgkg
h
administr
dose
tissu
plasma
ratio
h
administr
dose
similar
find
found
type
sinu
tissu
eg
maxillari
sinu
anterior
ethmoid
sinu
nasal
polyp
studi
sinu
mucos
concentr
well
valu
moxifloxacin
wide
rang
bacteria
studi
use
pharmacodynam
end
point
evalu
gatifloxacin
treatment
acut
maxillari
sinus
median
auc
sinu
aspir
plasma
sampl
rang
emerg
resist
fluoroquinolon
pneumonia
occur
mutat
gene
encod
target
topoisomeras
enzym
ie
parc
encod
subunit
dna
topoisomeras
iv
gyra
encod
subunit
dna
gyras
resist
pathogen
occur
discret
step
spontan
mutat
occur
initi
parc
secondarili
gyra
increas
evid
select
resist
pneumococc
strain
may
vari
among
respiratori
fluoroquinolon
new
pharmacodynam
mutant
prevent
concentr
mpc
develop
brief
mpc
concentr
requir
inhibit
growth
least
suscept
wildtyp
mutant
ie
singlestep
mutant
wherea
mic
lowest
concentr
need
stop
growth
wildtyp
bacteria
among
larg
number
clinic
isol
fluoroquinolonesuscept
pneumonia
n
moxifloxacin
found
fluoroquinolon
least
like
select
resist
mutant
follow
gatifloxacin
levofloxacin
addit
preliminari
vitro
data
suggest
auc
mic
may
protect
select
resist
pneumonia
mutant
moxifloxacin
clinic
trial
burk
et
al
report
first
find
efficaci
moxifloxacin
treatment
adult
patient
communityacquir
abr
ie
radiograph
evid
plu
baselin
sign
symptom
present
day
week
oral
regimen
either
moxifloxacin
mgday
cefuroxim
axetil
mg
bid
percentag
patient
clinic
respons
end
therapi
day
therapi
respect
clinic
relaps
rate
low
treatment
group
patient
receiv
moxifloxacin
patient
receiv
cefuroxim
axetil
siegert
et
al
conduct
multicent
trial
patient
random
receiv
mg
moxifloxacin
daili
day
compar
patient
receiv
mg
cefuroxim
axetil
twice
daili
day
clinic
success
rate
end
treatment
significantli
higher
moxifloxacintr
patient
cefuroxim
patient
ci
baselin
total
isol
moxifloxacintr
patient
cefuroxim
patient
obtain
use
middl
meatal
swab
cannula
evalu
efficaci
respons
rate
major
respiratori
pathogen
treatment
moxifloxacin
cefuroxim
axetil
follow
pneumonia
moxifloxacin
cefuroxim
axetil
h
influenza
moxifloxacin
cefuroxim
axetil
catarrhali
moxifloxacin
cefuroxim
axetil
rakkar
et
al
also
establish
moxifloxacin
mgday
least
effect
amoxicillinclavulan
mg
bid
clinic
resolut
testofcur
visit
ie
day
therapi
report
versu
patient
whose
result
could
evalu
efficaci
respect
gehanno
et
al
enrol
patient
prospect
studi
evalu
use
oral
moxifloxacin
mgday
day
treatment
acut
maxillari
sinus
firstlin
treatment
failur
well
patient
high
risk
complic
posit
plainfilm
radiograph
use
part
enrol
criteria
ninetytwo
patient
bacteri
isol
identifi
via
middl
meatu
cultur
pneumonia
h
influenza
rate
resist
penicillin
pneumonia
seri
h
influenza
isol
posit
efficacyvalid
patient
clinic
bacteriolog
success
rate
day
treatment
respect
klossek
et
al
compar
efficaci
oral
moxifloxacin
mgday
day
oral
trovafloxacin
mgday
day
patient
radiolog
proven
abr
evalu
perform
day
therapi
moxifloxacin
found
statist
equival
trovafloxacin
clinic
success
rate
vs
respect
correspond
clinic
success
rate
late
followup
visit
respect
common
caus
sinus
pneumonia
h
influenza
staphylococcu
aureu
bacteriolog
success
rate
posttherapi
evalu
similar
treatment
group
patient
given
moxifloxacin
patient
given
trovafloxacin
pool
analysi
clinic
openlabel
sinus
trial
efficaci
moxifloxacin
penicillinsuscept
penicillinresist
pneumonia
prsp
examin
patient
receiv
oral
moxifloxacin
mgday
day
patient
enrol
studi
patient
abr
caus
pneumonia
includ
confirm
case
prsp
infect
approxim
onethird
episod
consid
sever
accord
investig
evalu
clinic
bacteriolog
success
testofcur
visit
day
complet
therapi
occur
patient
prsp
infect
compar
patient
infect
pneumonia
regardless
penicillin
suscept
moxifloxacin
low
mic
valu
mgl
prsp
strain
result
small
cohort
patient
abr
caus
prsp
demonstr
effect
moxifloxacin
gatifloxacin
clinic
trial
larg
noncompar
studi
efficaci
gatifloxacin
mgday
day
evalu
adult
patient
abr
primari
pretherapi
pathogen
isol
catarrhali
produc
h
influenza
produc
pneumonia
penicillin
resist
aureu
among
patient
could
clinic
evalu
experienc
cure
major
pathogen
erad
second
studi
sher
et
al
evalu
efficaci
shortcours
gatifloxacin
regimen
mgday
compar
standard
regimen
either
amoxicillinclavulan
mg
bid
gatifloxacin
mgday
patient
acut
uncompl
maxillari
sinus
testofcur
visit
day
therapi
clinic
cure
rate
patient
could
clinic
evalu
given
gatifloxacin
day
given
gatifloxacin
day
given
amoxicillinclavulan
day
studi
suggest
select
patient
maxillari
sinus
shortcours
gatifloxacin
therapi
effect
levofloxacin
clinic
trial
least
compar
trial
establish
effect
levofloxacin
treatment
adult
abr
one
trial
total
patient
could
clinic
evalu
randomli
receiv
levofloxacin
mgday
amoxicillinclavulan
mg
amoxicillin
tid
mg
clavulan
tid
day
clinic
cureimprov
rate
day
therapi
levofloxacintr
patient
compar
patient
second
trial
patient
random
doubleblind
fashion
receiv
therapi
either
levofloxacin
mgday
clarithromycin
mg
bid
week
among
patient
could
evalu
clinic
cureimprov
rate
levofloxacin
compar
clarithromycin
followup
evalu
month
therapi
patient
receiv
levofloxacin
receiv
clarithromycin
experienc
relaps
symptom
although
studi
demonstr
effect
levofloxacin
abr
studi
conduct
almost
year
ago
prior
emerg
multidrug
resist
pneumonia
time
write
articl
publish
studi
evalu
efficaci
highdos
levofloxacin
treatment
abr
goal
antibiot
therapi
erad
bacteri
pathogen
site
infect
tout
failur
antibiot
achiev
goal
increas
potenti
clinic
failur
incur
cost
may
also
select
bacteria
resist
failur
often
due
infect
resist
pathogen
suboptim
pharmacokineticspharmacodynam
antimicrobi
agent
gwaltney
et
al
recent
examin
number
studi
abr
made
follow
recommend
patient
communityacquir
bacteri
sinus
episod
antimicrobi
treatment
administ
day
select
empir
agent
effect
common
antimicrobialresist
pathogen
includ
pneumonia
h
influenza
catarrhali
numer
treatment
guidelin
craft
worldwid
assist
practition
treat
patient
abr
collect
treatment
guidelin
north
america
countri
europ
reveal
amoxicillin
amoxicillinclavulan
commonli
recommend
agent
treatment
abr
macrolid
second
commonli
use
class
global
nation
guidelin
unit
state
franc
spain
recommend
either
role
limit
role
macrolid
concern
resist
pneumonia
intrins
poor
activ
h
influenza
respiratori
fluoroquinolon
posit
use
patient
moder
sever
diseas
histori
recent
antimicrobi
use
failur
improv
result
initi
therapi
h
environ
antimicrobi
resist
increas
rate
antimicrobi
resist
pneumonia
h
influenza
past
decad
made
select
empir
antimicrobi
therapi
mani
respiratori
tract
infect
includ
abr
challeng
role
mani
avail
oral
macrolid
treatment
respiratori
tract
pathogen
critic
junction
requir
close
suscept
monitor
failur
rate
often
high
accordingli
search
new
agent
fill
gap
continu
best
data
current
avail
use
pool
therapeut
outcom
model
predict
respiratori
fluoroquinolon
highdos
amoxicillinclavulan
optim
intrins
properti
lead
clinic
success
highdos
amoxicillinclavulan
continu
provid
high
success
rate
mani
mild
episod
abr
recommend
often
firstlin
therapi
mani
treatment
guidelin
includ
unit
state
fluoroquinolon
recommend
firstlin
therapi
patient
recent
histori
failur
associ
anoth
antimicrobi
presenc
moderatesever
diseas
patient
receiv
recent
nonquinolon
antimicrobi
therapi
prior
week
respiratori
fluoroquinolon
enhanc
activ
penicillinsuscept
resist
strain
pneumonia
highli
activ
strain
h
influenza
catarrhali
includ
produc
gatifloxacin
twice
activ
pneumonia
levofloxacin
moxifloxacin
even
potent
time
activ
levofloxacin
moxifloxacin
specif
shown
effect
treatment
abr
due
prsp
strain
respiratori
fluoroquinolon
shown
effect
treatment
patient
abr
clinic
trial
conduct
past
decad
although
fluoroquinolon
gain
larger
role
treatment
abr
clinician
must
use
fluoroquinolon
judici
appropri
maintain
activ
class
although
evid
outcom
clinic
trial
subtl
import
pharmacodynam
differ
among
wide
use
respiratori
fluoroquinolon
evid
differ
pharmacodynam
activ
pneumonia
wherein
gatifloxacin
moxifloxacin
predict
higher
serum
auc
mic
levofloxacin
may
discourag
select
resist
mutant
addit
free
drug
auc
mic
valu
appear
concentr
sinu
tissu
exceed
mpc
select
resist
strain
minim
present
respiratori
fluoroquinolon
recommend
secondlin
therapi
manag
mild
episod
abr
patient
histori
recent
antimicrobi
use
firstlin
therapi
patient
recent
receiv
antibiot
moder
diseas
allerg
effort
minim
inappropri
prescrib
fluoroquinolon
therapi
abr
import
maintain
integr
class
compound
select
potent
fluoroquinolon
ie
one
demonstr
optim
microbiolog
pharmacodynam
properti
utmost
import
increas
likelihood
clinic
success
discourag
emerg
resist
